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CQ-397 and CQ-414: antimicrobial activity and 
spectrum of two fluoroquinolone-cephalosporin, 
dual-action compounds with carboxamido bonds 
David M.Johnson and Ronald N. Jones 
Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, 
Iowa City, Iowa, USA 
Objective: To evaluate the potential spectrum of activity of two novel dual-action compounds vvith carboxamido bonds 
(CQ-397 and CQ-414; Laboratorios Aranda, San Rafael, Mexico) against human pathogens. 
Methods: Approximately 800 Gram-positive and Gram-negative aerobic clinical bacteria were tested in vitro using the 
Mueller-Hinton broth microdilution method of the National Committee of Clinical Laboratory Standards. 
Results: CQ-397 (cefamandole+enrofloxacin) and CQ-414 (cefamandole+norfloxacin) were equally potent against 
Enterobacteriaceae (MICgo range, 0.06-0.5 pg/mL and 0.06-1 ug/mL, respectively). Citrobacter freundii (MIC90, 4 pg/mL) 
and frovidencia spp. (MIGO, >32 pg/mL) exhibited elevated study drug MICs. Enterobacteriaceae resistant t o  
fluoroquinolones generally remained resistant. CQ-397 and CQ-414 were active against Stenotrophomonas maltophilia 
(MIGO, 4 pg/mL) and oxacillin-susceptible staphylococci (MI&, 0.25 pg/mL), but not oxacillin-resistant Staphylococcus 
aureus (MIC90, >32 pg/mL), Staphylococcus epidermidis (MIC90, 8 pg/mL), and enterococci (MICgos, 8 to >32 pg/mL). 
There was no difference in the dual-action drug activity (MIC90, 2 pg/mL) between penicillin-susceptible and -resistant 
pneumococci. Haemophilus influenzae and Moraxella catarrhalis were very susceptible (MIC range, r0.015-0.06 pg/mL) 
to  both compounds. 
Conclusions: The activity of these novel dual-action compounds, formed from the bonding of older antimicrobials, 
warrants further investigation for potential human and/or animal health use, including toxicology and pharmacokinetics. 
Key words: Dual-action compounds, older cephalosporins, enrofloxacin, norfloxacin 
I NTROD UCTl ON 
CQ-397 and CQ-314 are synthetic broad-spectrum, 
dual-action combination (LIAC) antimicrobials coii- 
sistiiig of a cephalosporin (cefaiiiandole-like) linked 
at the C-7 position by a carboxaniido bond to the 
fluoroyuinolones enrofloxacin and iiodoxacin, res- 
pectively. Aiiti~iiicrobial drugs having a dual mode of 
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action were first described two decades 'igo but, 
unfortunately, toxic side-effects limited their ther'i- 
peutic use [ I ] .  However, further development of ])A<: 
agents led to cornpounds that icoinbined the cell wall 
synthesis-iIihibitory action of a cephalosporin with the 
DNA gyrase-inhibiting activity of a quinolone 121. 
For example, Ro23-9424 (an t:stei--linked co-drug o f  
desacetylcefotaxiiiie aiid fleroxacin) has demonstrated 
potent activity against Enterobacteriaceae, staphylo- 
cocci, Stveprococc~rs spp ,  Haernophilus i r ! f h r r z n c ~ ,  
Movaxella catnvdinlis, Nrisscria spp. aiid ~ iu i i ie ro~~s  strailis 
resistant to fluoroquinolones or third-generation 
cephalosporin? [3,4]. Another IIAC, 1<025-0534 (a 
combination of a catechol cephalosporin and cipro- 
floxacin) was generally less potent than Ro23-9424, 
although it possessed superior activity against Strno- 
tvophornonas maltopldia and Pseirdomonas spp. IS]. 
335 
336 C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  Vo lume 3 N u m b e r  3, J u n e  1997 
CH, 





Figure 1 Chemical structures of CQ-397 and CQ-414 
CQ-397 and CQ-414 are structurally similar to the 
previously studied DAC K023-9424, and have a 
fluoroquinolone moiety that is linked at its 3' carboxyl 
group to the cephalosporin component. However, 
this structure could limit the candidate DAC to 
cephalosporin-like activity until the fluoroquinolone is 
released [2]. Unique to the new Aranda compounds is 
the carboxyamido bond at the C-7 position, in contrast 
to the 3'-position bonds utilized in previous DAC 
drugs. In this study, we evaluated the in vitro potency 
and spectrum of activity of CQ-397 and CQ-414 
(Figure 1) compared with cefamandole, enrofloxacin 
and norfloxacin. In addition, ceftazidime was added as 
a third-generation comparator cephalosporin because 
of its broader and more potent spectrum of activity 
with respect to cefamandole. 
R1 R2 Compound 
CQ-397 C2H5 Cyclopropyl 
CQ-414 H C2H5 
MATERIALS AND METHODS 
CQ-397, CQ-414 and enrofloxacin were provided 
by Laboratories Aranda, S.A. (San Kafael, Mexico). 
Cefamandole and cefiazidime were obtained from Eli 
Lilly and Co. (Indianapolis, IN), and norfloxacin from 
Merck, Inc. (Kahway, NJ). 
Nearly 800 Gram-positive and Gram-negative 
aerobic bacteria were tested (Tables 1-3). The 
organisms were recent clinical isolates (1 993-95) 
cultured from blood and other sterile body fluids (not 
including urine) in patients at  the University of Iowa 
Hospitals and Clinics (Iowa City, IA). The strains were 
stored at  -70°C and subcultured twice prior to being 
tested. 
Minimum inhibitory concentrations (MICs) were 
determined in cation-adjusted Mueller-Hinton broth 
microdilution trays (Prepared Media Microbiologics, 
Tualatin, OR). Fastidious organisms, such as Strepto- 
coccus spp., Corynebacteriurn jeikeiurn, Bacillus cereus and 
Haeniophilus influenzae, were grown in medium sup- 
plemented with 5% lysed horse blood. After overnight 
incubation, the trays were examined for growth and 
MICs were determined according to National Com- 
mittee for Clinical Laboratory Standards (NCCLS) 
methods [6,7]. Interpretive breakpoint criteria for 
norfloxacin, cefamandole and ceftazidime followed 
NCCLS [6] guidelines, while enrofloxacin and the new 
DACs were assigned the susceptible breakpoints of 
5 1 pg/mL and 5 8  pg/mL, respectively. 
RESULTS AND DISCUSSION 
Table 1 lists the results of the study compounds tested 
against 250 strains of Enterobacteriaceae. CQ-397 and 
CQ-414 were equally active (MICgo range, 0.06- 
0.5 pg/mL and 0.06-1 yg/mL, respectively) against this 
family of bacteria. Citvobacterjeundii (MICgo, 4 pg/mL) 
and the Pvovidencia spp. (MICeo, >32 pg/mL) demon- 
strated greater resistance to the DAC drugs; however, 
the comparison cephalosporins, cefamandole and 
ceftazidime, remained active against the Provideucia spp. 
strains (MICoo range, 0.25-4 pg/niL). Several species 
(Entevohacter aerogenes, Enterohacter cloacae, Klehsiella 
oxytoca, Mouganella rnouganii, Panteoa aggloinerans, Proteus 
vulgaris and Servatia rnarcescens) that exhibited resistant- 
range MIC results (MICgo, >32 pg/mL) to cefa- 
mandole were more susceptible to both IIAC drugs 
(MIC9o range, 0.25-1 pg/mL). In general, when the 
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Table 1 
NCCLS dilution methods 
CQ-397 and CQ-414 antimicrobial activity and spectrum tested against 250 Enterobacteriaceae clinical icolates by 
MIC (pg/tnL) 
Organism (no. tested) Antimicrobial agent 50% 90% Range u/;i Susceptihlea 
Gram-negative bacilli 
Citrobacterjeundii (20) 
Cifrobacter koseri (1 0) 
Enterobacter aeropzer (20) 
En teru barter cloacae (20) 
Ercherichia c ~ l i  (20) 

















































































































































10.015 to >32 
50.015 to >32 
50.008 to > 16 
0.015 to > 16 
0.5 to >3:! 







0.03 to >:52 
0.03 to >.52 
0.01 5 to >. 16 
0.06 to > 16 
0.5 to >?I:! 
0.06 to > 16 
50.015 to >,32 
0.03 to > 3 2  
10.008 to N 6  
0.03 to > 16 
1 to 2 3 2  
0.12 to > I6 
0.03-32 
0.03-32 
5 0.008-1 6 
0.03 to > Lb 
0.25 to >32 
50.03 to > 16 
0.06-0.2 5 
0.06-0.25 
0.0 1 5-0.1 2 
0.5 to >32 
0.06-0 5 
(1.06-2 
0.03 to > 32 
0.03 to > 32 
0.015 to >>16 
0.06 to > 16 
0.25 to > 12 
50.03-16 
0.06-0.23 
0.06-O. 2 5 
0.015-0.1 2 
0.01 5-0.1,6 
0.5 to >32 
50.03 to >16 
90 (85) 







































V O  
‘I i 
100 (1 00) 
100 
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Table 1-continued 
MIC (pg/mL) 
Organism (no. tested) Antimicrobial agent 50% 90% Range % Susceptible” 
Gram-negative bacilli 
Pantoea agRIomerans (20) 
Proteus mirabilis (20) 
Proteus vulpris (10) 
Providencia rettgeri (10) 
Provideitcia stuartii (1 0) 
Salmonella enteritidis (10) 
Serratia marcescens (20) 


















































































































































5 0.01 5-0.06 
5 0.008-0.03 
0.03-0.25 
0.25 to >32 











8 to 232 
50.03-0.06 
0.12 to >32 
0.12 to >32 
0.03 to >16 
0.03 to >16 
50.06 to >32 
50.03-0.5 
0.06 to >32 
0.06 to >32 
0.03 to >16 









0.25 to 232 
0.25 to >32 
0.06-16 
0.12 to >16 
4 to >32 
0.12-1 
50.015-0.06 





















































J o h n s o n  a n d  J o n e s :  I n  v i t r o  a c t i v i t y  o f  CQ-397 a n d  C Q - 4 1 4  339 
Table 1-continued 
MIC 
Organism (no. tested) Antimicrobial agent 50% 90% Range % Suweptihle' 
Gram-negative bacilli 












































50 .0084.25  
0.0 15-1 
0.25 to >:52 
0.06 to >'I6 










S O  
80 
"Breakpoint criteria per National Committee for Clinical Laboratory Standards [6] for norfloxacin, cefamandole and ceftazidime. The 
enrofloxacin-susceptible breakpoint was assigned at 5 1 yg/rnL (wne  as ciprofloxacin) and the commonly used cephalosporin breakpoint of 
5 8  pg/niL was applied to CQ-397 and CQ-414. The O/u susceptible values parentheses indicate the 5 2  pg/mL t'reakpoint. 
bIncludes six species: Enterobacfer rakazakii (two strains), Enterobacfer taylorae (two strains), Hafnia aluei (one strain), Klebsiella ozueiiae (one 
strain), Salmonella typhi (two strains) and Serratia liquefciens (two strains), 
Table 2 
clinical isolates by NCCLS dilution methods 
CQ-397 and CQ-414 antimicrobial activity and spectrum tested against various non-enteric Gram-negative 
MIC (pg/nL) 
Organism (no. tested) Antimicrobial agent 50% 90% Range 96 Susceptiblea 
Gram-negative bacilli 
Acinetobacter spp. (10) CQ-397 0.06 0.12 0.03-0.4 100 (100) 
CQ-414 0.06 0.12 0.03-0.5 1 00 (1 00) 
Enrofloxacin 0.03 0.06 0.015-0.1:1 100 
Norfloxacin 2 8 1-16 90 
Cefamandole >32 > 32 32 to >32 0 
Ceftazidime 2 8 1-8 100 
Psrudornona, aerrqinosa (30) CQ-397 1 16 0.5-32 77 (67) 
CQ-414 1 16 0.5-32 77 (67) 
Enrofloxacin 0.5 4 0.25-8 73 
Norfloxacin 0.5 2 0.25-4 100 
Cefamandole > 32 > 32 > 32 0 
0 Ceftazidime 2 8 0.5 to >16 
Stenotrophomonas maltophilia (10) CQ-397 1 4 
CQ-414 1 4 
Enrofloxacin 0.25 2 
Norfloxacin 8 >16 
Cefamandole > 32 >32 




4 to > I 6  












0.015 0.008-0.0 I5 
0.12 0.06-0.12 
4 2 4  
50.03 50.03 









































































































































5 0 . 0 3 4  12 
5 0.01 5-0.03 
50.015-0.06 
0.008-0.01 5 
8 to >32 
































"Breakpoint criteria per NCCLS 161 for norfioxacin, cefanlatldole and ceftazidime. The enrofloxacin susceptible breakpoint was assigned at 
S l  pg/mL (same as ciprofloxacin) and the commonly used cephalosporin breakpoint of 5 8  pg/mL was applied to CQ-397 and CQ-414. If 
a fluoroquinolone breakpoint ( 5 2  pg/niL) was used for CQ-397 o r  CQ-414, the spectrum is indicated in parentheses. 
activities of CQ-397 and CQ-414 are compared with 
those of their component fluoroquinolones (enro- 
floxacin and norfloxacin), the best component drug was 
two- to four-fold more active than CQ-397 and CQ- 
414. The spectrum and potency of the 'third- 
generation' cephalosporin comparator were superior to 
those of both DAC drugs. 
Table 2 contains the activity results for the study 
drugs tested against non-enteric Gram-negative 
organisms. The species causing respiratory tract in- 
fection, Haernophilus ivlfluenzae and Moraxella catarvhalis, 
were usually susceptible to all tested antimicrobial 
agents. Cefamandole had slightly elevated MICs for the 
P-lactamase-negative ampicillin-resistant (BLNAR) 
Haernophilus injuenzae strains, but none of the 
remaining compounds was significantly affected by 
strains possessing enzymatic or penicillin-binding- 
protein-mediated resistances. Norfloxacin (MICgo, 
2 pg/mL) was the most active compound against 
Pseudornonas aerqinosa. The DACs (MIC9o range, 
0.12-4 pg/mL) were more potent than the other core 
structure compound cefaniandole (MICyo, > 32 pg/ 
mL) against Acinetobacter spp. and Stenotrophotnonas 
rnaltophilia. 
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Table 3 
dilution methods 
CQ-397 and CQ-414 antimicrobial activity and spectruni tested against Gram-positive clinical isolates by NCCLS 
MIC (pg/niL) 
Organisin (no. tested) Antimicrobial agent 50% 90% Range o/o SusceptibleA 
Staphylococcus aureus 

























































































2 1 6  

































































0.12 to >16 
50.06-1 
4-1 6 
0.12 to >32 
0.12 to >32 
0.03 to > 16 
0.5 to >16 
1-32 








0.12 to >.32 
0.12 to >32 
0.03-4 
0.25 to >16 
0.5-8 







0.12 to > 12 
0.12 to 2.32 
0.03 to >16 
0.25 to > I 6  
2 to >32 
> I 6  
0.06 to > 12 
0.06 to > 12 
0.015 to :~16  
0.06 to >16 
0.12-2 
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Organism (no. tested) Antimicrobial agent 50% 90% 
Streptococcus 
Group B (20) 
Group C (10) 























































































































































































0.5 to >16 
1 to >32 
1 to >32 
1 to >16 
2 to 216 
16 to >32 
4 to > I 6  
1 to >32 
1 to >32 
4 to >16 
2 to >16 
32 to 232 
>16 
0.5 to >32 
0.5 to 232  
0.25 to >16 
8 to >16 
> 32 
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Table 3-continued 
MIC (pg/mL) 
Organism (no. tested) Antimicrobial agent 50% 90% Range 96 Susceptible,’ 
Entrvocorrur spp. 
Vancomycin-resistant 





Ceftazidiine > 16 
Covynebactevum jcikeium (1 0)  CQ-397 32 
CQ-414 32 
Enrofloxacin 16 
Nodoxacin” > 16 
Cefainandole > 32 






> l h  
1-8 100 (73) 
1-8 100 (hIJ) 
0.5-2 75 
4-8 27 
2 to >32 47 
>16 0 
> 32 0.25 to >.32 20 (10) 
> 32 0.25 to >32 20 (10) 
16 0.12 to > 16 1 0  
216  1 to >16 t o  
> 32 0.5 to >32 10 
>16 4 to >16 1 0 
CQ-397 0.06 - 0.06-0.12 100 (100) 
CQ-414 0.06 - 0.06-0.12 100 (100) 
Enrofloxacin 0.03 - 0.03-0.06 100 
Norfloxacin 0.25 0.25 100 
Cefainandolr 16 8-32 1 0  




’Breakpoint criteria per NCCLS [6] for norfloxacin, crfamandole and ceftazidime The enrofloxacin-susceptible breakpoint wa5 assigned at 
1 1  pg/mL (same a\ ciprofloxacm) and the commonly used cephalosporin breakpoint of 5 8  pg/inL was applied to C Q  397 and CQ-414 If 
a fluoroquinolone breakpoint ( 5 2  pg/mL) was used for CQ-397 or C Q  414, the Fpectruin is indicated in parentheses 
The activities of DAC drugs and the comparison 
compounds tested against Gram-positive organisms are 
listed in Table 3. Oxacillin-susceptible staphylococci 
were susceptible to CQ-397 and CQ-414 (MIC90 
range, 0.12-0.5 pg/mL); however, oxacillin-resistant 
Staphylococcus haemolyticus and Staphylococcus aureus 
strains had very elevated MIC results (256- and 128- 
fold, respectively). Although oxacilLin-resistant Staphylo- 
coccus epidermidis MICs were generally 16-fold greater 
than those of oxacillin-susceptible isolates, the vast 
majority (90%) still had DAC MICs of S8pg/mL.  
CQ-397 was less active (MICgo, 8 pg/mL) than the 
component drugs enrofloxacin (MIC9o, 1 pg/mL) and 
cefamandole (MIC90, 4 pg/mL) against oxacillin- 
resistant Staphylococcus epidermidis, indicating potential 
‘antagonism’. Only cefamandole had any measurable 
activity against oxacillin-resistant Staphylococcus haemo- 
lyticus. The remaining coagulase-negative Staphylococcus 
spp. were less susceptible to cefiazidime (40% resistant) 
than to the remaining studied antimicrobials. 
There was no difference in the CQ-397 and CQ- 
41 4 potencies (MICso, 2 pg/mL) between penicillin- 
susceptible and -resistant Streptococcus pneumoniae strains. 
CQ-397 had a slightly higher MIC (two- to 16-fold) 
than the component drugs against some P-haemolytic 
streptococci, again suggesting possible ‘antagonism’. 
DAC potency against Enterococcus spp. (100% sus- 
ceptible at 5 8  pg/mL) carrying the vanC gene was 
greater than that against vancomycin-susceptible strains 
(56% susceptible at 5 8  pg/mL). Both DACs were more 
active (MIC~O,  0.12 pg/mL) than cefamandole (MICW, 
32 pg/mL) and ceftazidime (MIC9o, > 16 pg/mL) 
against Bacillus cereus. All of the study conipounds 
(MIC90, 2 16 pg/mL) were inactive against Covyne- 
bacterium jeikeium. 
DAC antimicrobials continue to be promising 
agents with potential clinical use in humans and/or 
animals [l]. A wide variety of candidate cephem- 
fluoroquinolone combinations have been studied using 
various linking bonds. The use of older fused agents 
(norfloxacin+a second-generation cephalosporin) in- 
dicates that activity can be enhanced by this process and 
applications to human practice could include DACs 
with known safety and efficacy (component drug 
history). We anxiously await the results of expanded 
in vitro trials of CQ-397 and CQ-414, or similar 
compounds. 
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